Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (Anthim) [Elusys Protocol Number AH-102].

Next Previous
Search
Trial Profile

Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (Anthim) [Elusys Protocol Number AH-102].

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obiltoxaximab (Primary)
  • Indications Anthrax
  • Focus Adverse reactions
  • Sponsors EluSys Therapeutics

    • Most Recent Events

    • 14 Sep 2016 According to an Elusys Therapeutics media release, results from this study are published online at Clinical Therapeutics.
    • 24 Aug 2016 Results assessing safety, immunogenicity, and pharmacokinetics of this and other four studies published in the Clinical Therapeutics
    • 21 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top